CONCLUSIONS: Pharmacological treatment type and gender are important factors associated with heterogeneity in neurocognitive profiles in early childhood (4-6 years) ASD. These findings suggest that medication-related differences extend beyond behavioral symptom control and are linked to distinct sensory, regulatory, and executive functioning patterns. Clinically, this highlights the importance of considering treatment type and gender when interpreting neurodevelopmental profiles and when…
